Product Information

DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.8961 per EA under NDC 31722066660. Its NADAC has been published 100 times since Dec 18, 2024.

FDA first approved this application on May 6, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DABIGATRAN ETEXILATE 110 MG CP

Dabigatran Etexilate
$0.8961per EA

Strength

110 mg/1

NDC

31722066660

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA207961

FDA Approved

5/6/2020

TE Code

AB

On Market Since

8/13/2024

Pharmacological Classes

Direct Thrombin Inhibitor
Thrombin Inhibitors

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 100 times since Dec 18, 2024, and over the history we have for it it has declined 49.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.8961 per EA
All-time high$1.9786 (Apr 16, 2025)
All-time low$0.8961 (Oct 21, 2026)
52-week high$1.6053
52-week low$0.8961
Median price$1.6053
Average price$1.4547
Largest weekly change-12.4% (Dec 17, 2025)
Weeks tracked100
Tracking sinceDec 18, 2024

Price History

1W

0.0%

1M

-4.4%

3M

-8.0%

6M

-2.8%

1Y

-47.9%

3Y

N/A

5Y

N/A

All

-49.2%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?

The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Camber Pharmaceuticals Inc., is $0.8961 per EA (NDC 31722066660), effective Nov 11, 2026.

How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?

Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 49.2%. It has been tracked across 100 weekly CMS publications since Dec 18, 2024.

What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?

Since Dec 18, 2024, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.8961 (Oct 21, 2026) to a high of $1.9786 (Apr 16, 2025), with a median of $1.6053 per EA.

Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?

4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, but none are currently priced below it.

Who manufactures DABIGATRAN ETEXILATE 110 MG CP?

DABIGATRAN ETEXILATE 110 MG CP (NDC 31722066660) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.